Charity
Report
2 0 2 3 - 2 4
OUR MISSION
Using our scientific network across the UK, we champion and accelerate innovative eye disease research. Through targeted investment into the most promising science, we will deliver meaningful impact for those living with sight loss.
OUR VISION
A clearer future for those living with sight loss.
SIGHT RESEARCH UK | CHARITY ANNUAL REPORT 2023 - 2024
Contents
|
Welcome from our Chair |
4 |
|---|---|
|
Hello from our CEO |
5 |
|
Highlights of the year |
6 |
|
Research locations |
7 |
|
Our Finances 2023 - 2024 |
8 |
|
Our Active Research |
9 - 10 |
|
- Could a point-of-care test diagnose a dangerous fungal eye infection? |
|
|
- Can eye imaging in children reduce unnecessary hospital referrals? |
|
|
Our Completed Research |
11 - 12 |
|
- Could surgery-free brain stimulation successfully treat glaucoma? |
|
|
- Are there genetic differences between those who develop AMD and those who don’t? |
|
|
Spotlight on our Supporters |
13 - 16 |
|
- Tricia's Story |
|
|
- The Owls of Pill |
|
|
- Brightening Lives at Christmas with Newmedica |
|
|
Get involved |
17 |
|
Leave a legacy |
18 |
|
Thank you |
19 |
WELCOME FROM OUR CHAIR
Our work at Sight Research UK goes from strength to strength, and in a year in which the charity has seen internal restructuring to put us in the strongest position to deliver our work, we steadfastly continue on our path to deliver our exciting research strategy, funding the most promising translational research to improve the lives of those living with, or threatened by, sight loss.
We welcomed our new Grants Manager and Marketing & Communications Manager early in 2024, which has had a positive impact on promoting and delivering our funding programmes. In addition, we increased our capacity to secure funding, charity governance, and administration. This provides a solid foundation for the charity to grow and prosper into 2025.
Carol Mayo, Chair of Trustees
We said goodbye and a sincere thank you to Charlotte Parkin for all her hard work and dedication over the last two years. We welcomed Lucy Culkin as our new CEO. Lucy joins us as an experienced Chief Executive Officer with many years of experience in charity management and governance.
We continue to feel the increased financial strain across the UK, making fundraising ever more competitive. Trustees recognise this risk to all charities and have been supportive in enabling the team to build in capacity to increase and strengthen our campaigns for future funding.
Our donors and supporters remain our greatest strength, and we are so grateful for their continued generosity, which ensures we can deliver our purpose of turning science into real-world tools for diagnosis, treatments, and prevention.
I am delighted to be able to share this Charity Report for the financial year 2023-24 with you all and hope you enjoy learning of just some of the work your kind support has enabled.
Lastly, I would like to take this opportunity to thank my fellow trustees for their unwavering dedication to the charity over the past twelve months. I very much look forward to working with them throughout this next year.
My thanks also to all our donors, volunteers, patients, researchers, team, and trustees.
HELLO FROM OUR CEO
Welcome to Sight Research UK’s Charity Report 2023-2024. I am delighted to introduce myself as the new Chief Executive, taking over the role from Charlotte Parkin in December 2024.
I joined Sight Research UK after completing five years as CEO of a conservation charity; prior to this, I worked for national charities in senior leadership roles. I hope to bring my 25 years of experience to the charity and build on its many successes into 2025 and beyond.
When I applied for the role at Sight Research UK, I was impressed & intrigued by its work. The medical research sector is new to me, and I have a lot of learning to do, but within my first few months here, I‘m assured of the growing need for vision research. I’m looking forward to understanding more about our funded research and its impact on those living with sight loss, as well as the institutions & professionals pioneering new treatments.
What’s clear in the early days of my tenure is that with an ageing population and lack of funding in the sector, the pressures on our NHS & high street eye care providers are greater than ever, so it falls to us in the charity sector to ensure that sight research does not lag behind.
This report features some of the fantastic projects we’ve been funding. One of many highlights is Dr Beth Mills from the University of Edinburgh, who’s conducting research into lateral flow testing to rapidly diagnose a sight-threatening fungal eye infection (read more on page 9).
To further expand our reach, we partnered with Newmedica for our 2024 Christmas campaign, and thanks to your generous support, we smashed our fundraising target by mid-December!
Lucy Culkin, Chief Executive
Newmedica has committed to supporting us again in 2025, and I‘m excited at the opportunity to build on this partnership in the years to come.
We said goodbye to one of our trustees in 2024. As always, we‘re grateful to our trustees for giving their time and expertise to the organisation (the outgoing trustee has been listed on page 19).
Thanks to our dedicated trustees, the staff team, and Charlotte for the work delivered in the 2023/24 financial year.
Finally, I‘d like to give sincere thanks to our supporters and donors. It‘s my intention to understand the motivation for supporting our charity. I‘m committed to engaging & communicating the value and impact of our work as widely as possible and welcome your feedback. We look forward to another successful year and bringing the Sight Research UK community along with us.
HIGHLIGHTS OF THE YEAR
We’ve had such an incredible year at Sight Research UK. From 2023 to 2024, we supported 26 sight research projects across 13 institutions based all over the UK. From inherited to environmental, common to rare, we have fuelled research into eye conditions affecting all ages.
This year, we funded research into sight conditions including Age-related Macular Degeneration, Corneal conditions, Glaucoma, Myopia, Retinitis Pigmentosa, Diabetic Retinopathy, Fungal Keratitis, Keratoconus, OcMMP, amd Ocular Inflammatory Disease. All the project topics are listed below:
Key statistics:
RESEARCH LOCATIONS
- University of Edinburgh
- Queen's University Belfast
- Ulster University
- Sheffield Teaching Hospitals NHS Trust
- University of Leicester
- University of Lincoln
- North West Anglia NHS Foundation Trust
- University of Birmingham
- University of Bristol
- Moorfields Eye Hospital
- University College London
- University of Southampton
- University of Plymouth
OUR FINANCES
2 0 2 3 - 2 0 2 4
INCOME
- Donations (including gift aid): £428,917
- Legacies: £295,701
- Investments: £71,636
- Gifts in kind: £5,000
- Other trading activities: £1,487
Income total: £802,741
EXPENDITURE
- Research: £519,017
- Charity management & governance: £275,257
- Fundraising costs: £19,956
Expenditure total: £814,230
We employ five members of staff.
Our Active Research
Could a point-of-care test diagnose a dangerous fungal eye infection?
Most people in the UK will be familiar with an at-home pregnancy test or a Covid-19 test. Both are common lateral flow devices (LFDs), which are increasingly used to diagnose many different health conditions.
Thanks to Sight Research UK funding, microbiologist Dr Beth Mills is developing an LFD to rapidly diagnose a sight-threatening eye infection called microbial keratitis, which could ensure patients receive effective treatment straight away.
Patients with microbial keratitis are usually given antibiotic eyedrops. These usually work well if the infection is bacterial. But for fungal infections, which are less common in the UK, antibiotics don’t work. It takes up to two weeks to get a fungal diagnosis, and even then, around half of lab tests fail to identify the pathogen causing the infection. Any delay in treatment increases the risk of surgery and often leads to vision impairment.
Beth’s two-year project is both multidisciplinary and international. At the University of Edinburgh’s Centre for Inflammation Research, her team is identifying suitable antibodies that can be put into an LFD. Prototype devices are manufactured by a commercial company and then returned to the lab for validation. The most promising devices are then sent to a clinical partner in India – where half of all cases of keratitis are fungal – to be tested on patient samples. Meanwhile, back in Edinburgh, computing students are building a smartphone app to help accurately determine whether the LFD result is positive or negative.
“Working across disciplines and with partners means that we can prototype and develop really rapidly. We say that we want to ‘fail fast,’ iterate, and move on.”
If the project is successful, a cost-effective, point-of-care LFD for fungal keratitis will be ready for clinical trial and regulatory approval – crucial steps to undertake to bring this product to market.
“It’s exciting that funding is available for these really innovative, translational projects that have a potential to transform the landscape for diagnostics. Small charities such as Sight Research UK have to be really careful about where they put their resources, so I definitely feel a sense of responsibility to make sure that we deliver results.”
Can eye imaging in children reduce unnecessary hospital referrals?
Looking at the back of the eyes is a routine part of most eye examinations. In children, optometrists do this to check that the optic nerve head looks healthy. However, many optometrists say that when examining children, it can be challenging to be sure about the health of the optic nerve head. This leads to many unnecessary hospital referrals.
Thanks to a Sight Research UK grant, researchers are investigating whether a new modelling approach using images from digital cameras and laser scanners could improve how children’s eyes are examined.
The team are collecting a small library of optic nerve head images from healthy children. They will then use a modelling technique similar to the way ‘Face ID’ works on a smartphone, extracting a set of numbers from points on the images that most efficiently describe the optic nerve shape.
“Today we’re doing our first ‘photoshoot’ at a local school. We’re seeing that although the optic nerve head in a child is smaller than in an adult, it has the same amount of nerve tissue, so the area can look more crowded. High street optometrists can misinterpret this natural crowding as a sign of papilloedema or optic nerve head swelling.”
With further funding, the images will be tested with optometrists to assess whether they can help them to spot suspected abnormalities more effectively.
The team intend to make the image library freely accessible to other researchers as part of the Open Science Framework.
“This grant is allowing us to gather precious pilot data on the optic nerve head in children – data which, to our knowledge, doesn’t exist anywhere. It has been transformative, helping us to start conversations and make plans for collaborations that should lead to real improvements in children’s eye care on the high street.”
Our Completed Research
Could surgery-free brain stimulation successfully treat glaucoma?
Neuroscientist Dr Daniel Whitcomb and his team of PhD students specialise in ultrasound brain stimulation. This is a quick and painless technique that can target an area in the brain the size of a coffee bean to stimulate activity.
Daniel’s team had previously shown that this technique could increase production of a molecule called brain-derived neuropathic factor (BDNF), which protects cells damaged in neurodegenerative diseases.
When Daniel read about experimental surgery that had increased these molecules sufficiently to protect retinal cells in an animal model of glaucoma, he wondered if ultrasound brain stimulation might have a similar effect. He applied for Sight Research UK funding to find out.
Their experiments, using anaesthetised healthy rats, found that ultrasound brain stimulation did increase the amount of BDNF molecules in the retina. Importantly, other areas of the brain were completely unaffected.
“It’s extremely promising, but there are questions still to be answered,” Daniel says. “We don’t know how long the effects of an ultrasound session last. And while we've shown we can increase the amount of BDNF, we don’t know if that increase is sufficient to have a protective effect against glaucoma itself.”
With further funding, Daniel’s team will be able to find answers, testing the technique in an animal model before exploring early-phase clinical trials.
Ultrasound brain stimulation is already being trialled in Alzheimer's disease and Parkinson's treatments. If it proves to be safe and effective for glaucoma, it could pave the way for patients being treated in as little as 15 minutes with a targeted brain scan that could stop symptoms getting worse.
“Proof of concept research is high risk, high reward,” Daniel says, “because if your hypothesis is wrong, you end up with nothing. That’s why this kind of funding is so hugely important.”
“We had pilot data on something completely unrelated to glaucoma, but we really thought that it might be relevant. The grant gave us the chance to apply this knowledge and, in this case, our findings could lead to better ways to treat glaucoma and other degenerative eye disorders.”
Are there genetic differences between those who develop AMD and those who don’t?
200 million people worldwide have age-related macular degeneration (AMD), an incurable eye disease that leads to sight loss.
It’s thought that the immune system plays a key role in the disease. Immune cells called macrophages collect at sites of injury in the eye and help the body’s immune response, removing debris that could affect sight and regulating tissue repair. However, as we age, macrophages change and become less efficient, meaning diseases or inflammation are more common.
Macrophages appear to be affected in AMD patients, but it’s not known why. Disease modeller Dr Evangeline Foster secured Sight Research UK funding to try to find out.
Working with Dr Amanda Carr at UCL’s Institute of Ophthalmology, Evangeline used an advanced technique called RNA sequencing to examine the genetic differences between macrophage cells generated from healthy older and younger individuals and from AMD patients.
“This technique measured every single gene expressed by the cells, so it produced a lot of data,” Evangeline explains. “Our analysis showed differences in genes between the disease and non-disease groups, which is exciting because it means we will now be able to identify genes that are relevant to AMD.”
Understanding early changes in AMD at a genetic level is crucial. It will help scientists to identify clinically relevant biomarkers that could predict the risk of developing the disease and targets for drugs that could slow or stop its progression.
“This funding gave me a vital platform as an early-career researcher, and I’m so grateful for it,” Evangeline says. “I’ve been able to go to conferences to present our findings, and I’m now training others to use the same sequencing technique.”
“Not only has it helped me, but it will also have a snowball effect for future post-docs and for the lab itself. Having this data means we can apply for other grants which will build on our knowledge, taking us a step closer to finding effective treatments for AMD or even preventing it altogether.”
SPOTLIGHT ON OUR SUPPORTERS
- Tricia's Story
- The Owls of Pill
- Brightening Lives at Christmas with Newmedica
TRICIA'S STORY
Back in 2014, Tricia joined her best friend Cathie on a beachfront walk. Out of nowhere, “I heard a popping sound. I lost sight in my right eye, and it went completely black,” says Tricia. She dismissed it at first as a bit of sand that got stuck in there. After a visit to the pharmacist, and later to an optometrist, Tricia began to worry that the problem was something more troubling.
Following a brief trip to Exeter’s ophthalmology department, Tricia was referred to specialists at The Bristol Eye Hospital, who carried out many tests and eye exams. They told her she had chorioretinopathy, a rare form of uveitis. With steroids, doctors could happily restore some of Tricia’s sight. “I was still driving at this time; I was still doing everything. But six months later to the day, my left eye popped.”
Now with limited vision in both eyes, and feeling as though her entire world had ended, Tricia turned her back on it altogether. She resolved never to leave her home— and she didn’t, not for a whole year. “I spent the year I was 39 sitting in the house.” Tricia did not expect how much her life was about to change when a stranger knocked on her door one day.
The lady at the door worked as a rehabilitation officer for the visually impaired. She asked Tricia if she’d be kind enough to show her to the local shop. For the first time in months, Tricia got out of her pyjamas and stepped out of her front door. “I held onto her leg like a little child that was so scared.” When they left the shop, Tricia asked the woman how she was getting home. “She said, “I’ve got a driver. I’ve got no eyesight whatsoever.” This kind stranger, who was born blind, yet who perseveres, who works, who leaves her home, brought Tricia back to life.
Tricia started venturing out. It began small- a stroll around her village. Then, further, into town to run errands. Each day her confidence grew. She even signed up for walking marathons and a tough 100-kilometre non-stop walk. “I’d started believing in myself a little bit. And I realised that I needed to do something different.” So Tricia applied for BBC Race Across the World, putting Cathie’s name down for good measure. Months later, having forgotten all about it, Tricia got a phone call inviting her and Cathie to take part in Series 3. Contestants spent 8 gruelling weeks racing across Canada with little to no money and no contact with family or friends. Tricia had no one but Cathie by her side. After those long weeks hitchhiking, Tricia and Cathie were the first pair to reach the final checkpoint, becoming the winners of BBC Race Across the World Series 3. “I would never have done it with anybody else. It was the hardest, most brain-fogging thing I've ever done, but I have the most amazing, adrenaline-filled memories ever.”
Despite her win, upon returning to work, Tricia saw little change in people’s reactions to her sight condition. So two months on from her Canadian adventure, Tricia jetted off to Peru. Five days into a trek up the Inca Trail, at the summit, she had an epiphany. “They're telling me I can't do anything because I'm blind. I’ve just raced across the world and now I've walked up Machu Picchu.” So right at the top of the mountain, she called her now-manager to ask for a job with the RNIB, where she’s worked ever since.
Today, Tricia has less than 5% visibility in her right eye and 9% in her left eye. But she’s not afraid of going blind anymore. “I used to be absolutely petrified. Now it doesn't bother me because I know that there's support there.” Since that fateful beach walk, Tricia has trekked thousands of miles, spanned countless countries and oceans, and met so many inspirational people on the way. Yet, the most difficult strides she ever had to take were the first few out of her own front door.
THE OWLS OF PILL
In the words of Henry James, it takes an endless amount of history to make even a little tradition. And traditions sing out in earnest when it comes to the Owls of Pill, an all-male group of carollers situated in a small Somerset village.
From their carols to their cloaks to their charitable mission, very little has changed since the Owls began back in 1919. “We were founded by the Reverend Robert Griffith as a sort of youth club. Kids used to go out and sing in the village, collect money, and hand it over to the blind,” says Chairperson Brian Davis. After the Great War, there was a call for funding to help wounded soldiers - particularly those suffering from the blinding effects of mustard gas. To this day, the Owls of Pill have continued their philanthropic ties with sight loss charities, including ours!
Sight Research UK is honoured to have received donations from the merry chorus since 2002.
Come Christmas time, the Owls flock to pubs, schools, hospitals, and homes across North Somerset and Bristol, donned in their Dickensian garb. “Since the 1940s the Owls have worn top hats and big coats because they were singing outside all the time,” adds Brian - a habit that endures to this day. These songbirds sing all the carols of old, from “Hail Smiling Morn” to “God Rest Ye Merry Gentlemen” (Brian’s personal favourite).
Brian is a retired schoolteacher and has been part of the Owls for 43 years since watching them in a local performance. He particularly loves to involve the little ones who come to watch. “I keep an eye out to see if there are any particularly confident children” to lead the most popular tunes, such as “Away in a Manger.”
After their songs cease, the singers are often approached by touched audience members. “They've all got personal stories... some have tears in their eyes. You realise that Christmas time pulls on heartstrings for a lot of people.”
Brian has a more intimate connection to the carollers’ original mission since being diagnosed with macular degeneration several years ago. “I speak from personal experience: keep going with the sight research. It's probably a bit late for me, but somebody will benefit along the line.”
We are so privileged to be a part of the Owls’ proud history. We hope that their fierce traditions, which spread unbound joy and merriment, will continue for generations and generations to come.
BRIGHTENING LIVES AT CHRISTMAS WITH NEWMEDICA
First off, we’d like to say a huge thank you to all of our supporters. Your generous gifts this festive season amounted to £12,677.50, making it our most successful public appeal to date. This truly wonderful outcome will go towards supporting crucial sight-saving research projects.
We were also incredibly touched to have had a pledge of up to £10,000 in matched funding from Newmedica. This meant that donations to our Christmas appeal, ‘Brightening Lives Through Vision Research,’ could be matched up to this figure. A donation of £10 became £20, a donation of £50 became £100, and so on.
However, upon hearing that our campaign had hit the matched funding target within the first few weeks of December, Newmedica decided to increase their £10,000 pledge. They committed instead to matching every single pound and penny you raised during the festive season. So, Newmedica’s generous gesture took our total, with each gift matched, to over £25k.
Together, your donations went twice as far to spark hope and brighten futures. Your kind gifts brought the final total to £28,136.54, which includes Gift Aid.
Our Chief Executive, Lucy Culkin, says,
“We have been blown away by the generosity of our supporters this Christmas. Your contributions will make a sustained impact now and into the future. Thanks to you, we can continue to invest in crucial research, without which none of the treatments, diagnostics, and devices used to tackle sight-threatening conditions would exist. We are incredibly grateful to Newmedica, who have been dedicated to our appeal. Thank you all for your extraordinary support.”
Newmedica cares for more than 165,000 NHS and private patients a year in more than 30 locations across England. They work with the NHS as well as local GPs and opticians to help treat and manage a range of advanced eye conditions in local communities.
Get involved
From activities requiring (almost) zero effort to going the extra mile – there are lots of ways to get involved and help us beat eye disease.
1Run for our charity
Are you an avid ambler, recreational runner, or happy hobbyist? Is someone you know? Well, look no further! Through ‘Run for Charity,’ we offer access to a wealth of events to suit all ages and abilities. The best part? Along with your commitment to get fit, have fun, or just spend time outside, you’ll be fundraising for the Sight Research UK cause! Sign up solo or with friends– the choice is yours. Contact us or check out what’s on offer in your local area here:
www.sightresearchuk.org/how-you-can-help/fundraising/run-for-charity/
2Regular Individual Giving
Making a regular gift to Sight Research UK has a sustained impact on our ability to affect future change. Regular giving means charities like ours can look ahead. We will have the support to fuel research ventures every year that pave the way to real impact for those affected by eye disease. Donating monthly is more convenient too - making gifts little and often will add up, just like saving. And you can feel reassured that your investments are being put to good use! Contact us to find out more.
3Share your story
By sharing your experience of living with sight loss or an eye condition, you can help us raise awareness of why it is so important that we continue to fund research in pursuit of new treatments for sight-threatening diseases. We’d love to hear from you, so if you’d like to share your story, you can:
- Call us: 0117 325 7757
- Email us: hello@sightresearchuk.org
- Write to us: FREEPOST Sight Research UK, Equinox South, Bradley Stoke, Great Park Road, Bristol, BS32 4QL
- Fill out our online form: www.sightresearchuk.org/ways-to-give/share-your-story/form/
4Corporate Partnership
We are always looking to build connections with local and national businesses that share our passion to deliver a meaningful impact to those living with sight loss. From team building to raising brand awareness, corporate partnerships can offer many benefits. Why not choose us as your charity of the year?
5Leave a legacy
One of the most powerful and joyous things you can do to fight sight loss is to leave Sight Research UK a gift in your Will. A legacy is often the largest gift anyone can ever afford to make, and doesn’t require parting with any funds while they’re needed. No child, parent, or grandparent should have to face a life forever altered by sight loss. Every day, your legacies are helping scientists discover new treatments for eye disease, and new ways of preventing blinding conditions. Lasting gifts ensure a clearer future for those living with sight loss and blindness.
If you are considering a gift in your Will – thank you. Every gift makes a difference, regardless of size. A gift of even 1% of your estate, so those closest to you get 99%, is invaluable. All you need to give to your professional adviser is our charity number: 1156134
If you would like your legacy to be used for a specific area of sight research, please contact us:
0117 325 7757 or hello@sightresearchuk.org
We will be happy to discuss your wishes with you and you can change your mind at any time.
In 2018, the UK government, charities, and other public agencies invested £1.4 billion in medical research. Just over 1.5 % (£24 million) of that was for eye research. 2.6% was invested in research for respiratory diseases, 9% for cancer and neoplasms, and 9.6% for neurological conditions- including dementia. To put this in perspective, only £9.60 is invested into research for each and every person living with sight loss. Ten times this amount is allocated to dementia research, at £97 per person per year.
This is simply not good enough.
Despite its profound potential, sight research is critically underfunded. Ophthalmology is the busiest NHS outpatient speciality in the UK, yet sight-saving treatments cannot keep up with demand. As a result, 22 people lose their vision weekly to preventable causes. Potential new treatments will take far longer to develop without increased investment in sight research. With your help, we can bring researchers ever closer to scientific breakthroughs with the power to transform lives for good.
Thank you
None of the work we do would be possible without the unwavering generosity of our supporters. Thanks to you, we can continue to invest in crucial sight-saving research. We wish we could acknowledge everyone here, but below are some of the many people and groups who have contributed to our success in the 18 months to 31 December 2024.
Groups, Trusts & Foundations who made gifts over £500:
- Anonymous (16)
- Condon Family Trust
- James Tudor Foundation
- Misses Barrie Charitable Trust
- Robert Luff Foundation
- The Basil Brown Charitable Trust
- The Ian Askew Charitable Trust
- The Owls of Pill
Individuals who made gifts over £500:
- Anonymous (10)
- Spencer Cleminson
- Peter Cook
- John Cottrell
- Geoffrey Church
- Robert Drewett
- Susan Harrow
- H Hickman
- Diane Liell
- Alan Martin
- Sheila Miller
- Philippa Neaverson
- Jane Pope
- Imelda Rice
- Nicholas Rogers
We received donations in memory of:
- Carole Copley
- Stanley Eaton
- Ann Harrow
- Elizabeth Hayes
- John Jeff
- Alice Little
- Karl Reed
- Stuart Savage
- Marguerite Sinclair
- Rose Wallace (McKenzie)
We received legacies from:
- Hazel Ashton
- Margaret Backhouse
- Glenda Boughton
- Martin Davies
- Joseph Goodworth
- Pauline Haynes
- Peter Lawrence
- Angela McMahon
- Valerie Saunders
- Patrick Sims
- Mary Timbrell
- Evelyn True
- Jacqueline Vockings
Our Trustees:
- Mr Simon Bowker (Treasurer)
- Dr Dolores Conroy
- Mr Robert Drewett DL
- Dr Rosie Gilbert **
- Prof John Greenwood
- Mr Clive Hetherington
- Mr Phillip Jackson (Vice Chair)
- Mrs Carol Mayo (Chair)
- Miss Serena Salvatore
- Mr John Swarbrick
** stepped down in the 18 months to 31 Dec 2024
Our Vice Presidents:
- Prof John Armitage OBE
- Prof Andrew Lotery MD FCROphth
- Prof John Marshall MBE
- Lady Wills
Our Research Advisory Board:
- Prof Matthew Campbell (Vice Chair)
- Prof Tim Curtis
- Dr Annegret Dahlmann-Noor
- Dr Lisa Hill
- Dr Pirro Hysi**
- Dr Hari Jayaram**
- Prof Glen Jeffery**
- Dr Victoria Kearns
- Prof Reinhold Medina
- Prof James Morgan**
- Prof Luminita Paraoan (Chair)
- Dr Salman Rahman
- Miss Teresa Sandinha
- Prof Mitra Tavakoli
- Dr Marta Ugarte**
- Prof Colin Willoughby
** retired in November 2024
Our Seed Panel:
- Dr Laura Cushley
- Dr Jennifer Dewing
- Dr Hannah Dunbar
- Mr M J Gilhooley (Vice Chair)
- Dr Philippa Harding (Chair)
- Dr Liying Low
- Dr Naseeb Kaur Malhi
- Dr Ben Mead
- Dr Mike Powner
We would also like to thank all the External Expert Reviewers who took the time to review research funding applications.
Sight Research UK is a Charitable Incorporated Organisation, registered with the Charity Commission of England and Wales (1156134).
Built with Shorthand